Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of isolated pelvic perfusion with TNF-alpha and melphalan versus standard treatment for locally advanced pelvic tumors
2008-007412-15Phase 3Active
- Sponsor
- Gustave Roussy
- Start
- Mar 2009
- Modality
- Small Molecules, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan and tumor necrosis factor-α in pelvic mass, gynecological cancer and gastrointestinal cancer (2 arms), sponsored by Gustave Roussy. Primary endpoint: Overall survival at 1 year. Started Mar 2009; status: active.
02
Drugs
melphalantumor necrosis factor-α
03
Conditions
pelvic massgynecological cancergastrointestinal cancer
Beyond the preview
Go deeper on 2008-007412-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007412-15.